EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Systemic immune dysregulation in patients experiencing urogynaecological mesh failure

Shannon Jamieson iD, Cameron R Dougan, Eloise Rennie, Patrick Card, Sudarshan Nallappa, Karen Smith, David J Deehan, Karen Brown, Catharien M U Hilkens, Christopher Harding

BJUI Compass · 2026-05 · 7 (5)

DOI: 10.1002/bco2.70210 ↗

At a glance

Journal article in BJUI Compass, published online on 2026-04-30. Written by Shannon Jamieson and 9 co-authors. Institution: Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK. Cited 1 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objectives

This study aimed to investigate the systemic immune landscape in patients experiencing urogynaecological mesh failure. The use of urogynaecological mesh was paused in the UK following an independent safety review that found ~1 in 15 women required removal due to complications. However, the mechanisms underpinning mesh failure remain largely unknown, with few studies focussing on localised tissue responses and no reports characterising systemic immune dysregulation. Materials and methods Serum samples collected from patients during mesh removal surgery were analysed for immunomodulatory protein content using enzyme‐linked immunosorbent assay (ELISA) and multiplex Luminex Discovery Assay. Peripheral blood mononuclear cells (PBMCs) collected were cultured with or without exposure to pristine mesh, and immunomodulatory protein secretion was measured in the same way. Patient serum was also used as a migratory stimulus for healthy PBMCs to test the functionality of chemotactic proteins present.

Results

Mesh patient serum had increased chemotactic protein levels, particularly CCL2, CXCL5, CCL12 and CCL4, which had a functional effect and induced significant cell migration. Mesh patient PBMCs also secreted immunomodulatory proteins including MMP‐9 and CCL2. Future studies should focus on expanding cohort numbers and including a control group of mesh patients not experiencing complications to further determine both underlying biology and mesh responses.

Conclusions

This study characterised an altered systemic immune landscape not previously investigated in mesh failure patients. Clinically, the ability to identify phenotypic factors or develop biomarkers which predict and monitor mesh responses would help guide clinicians and patients in shared decision making.

Subjects

Author keywords

cell migrationchemotaxisimmune systeminflammationlower urinary tract symptomsmesh

Authors and institutions

  • Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK.
  • Newcastle Hospitals NHS Foundation Trust Newcastle upon Tyne UK.

ORCID profiles: Shannon Jamieson

Cite

APA

Jamieson, S., Dougan, C. R., Rennie, E., Card, P., Nallappa, S., Smith, K., Deehan, D. J., Brown, K., Hilkens, C. M. U., & Harding, C. (2026). Systemic immune dysregulation in patients experiencing urogynaecological mesh failure. BJUI Compass, 7(5). https://doi.org/10.1002/bco2.70210

Vancouver

Jamieson S, Dougan CR, Rennie E, Card P, Nallappa S, Smith K, et al. Systemic immune dysregulation in patients experiencing urogynaecological mesh failure. BJUI Compass. 2026;7(5). doi:10.1002/bco2.70210

BibTeX
@article{Jamieson2026,
  author = {Jamieson, Shannon and Dougan, Cameron R and Rennie, Eloise and Card, Patrick and Nallappa, Sudarshan and Smith, Karen and Deehan, David J and Brown, Karen and Hilkens, Catharien M U and Harding, Christopher},
  title = {Systemic immune dysregulation in patients experiencing urogynaecological mesh failure},
  journal = {BJUI Compass},
  year = {2026},
  volume = {7},
  number = {5},
  doi = {10.1002/bco2.70210}
}
Start for free →